12 research outputs found

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Epidemiologic and epigenetic instruments to study mechanisms involved in prostate cancer relapse

    Get PDF
    Prostate Cancer (PC) is the most common cancer in elderly males (>70 years) in Europe, but also American and African populations are characterized by high incidence and mortality related to this malignancy. Incidence rates of PC became higher after the introduction of the Prostate Specific Antigen (PSA) screening. Actually, there isn’t a unique method to treat this pathology, so several therapeutic procedures could be used. The treatments frequently used are watchful waiting, prostatectomy and radiotherapy however often a pharmacological treatment is also used (in particular the anti-hormonal medications); sometimes two different options are used. The main aims of this study are the following: 1) Study the use of medications in patients with a diagnosis of PC in Friuli Venezia Giulia considering the period between 1998 and 2014. 2) Study the methylation status of a part of the Glutathione S-transferase Pi 1 (GSTP1) promoter in patients who underwent Radical Prostatectomy (RP) and try to understand if methylation of this promoter could influence the risk of relapse. 3) Study the features of patients who underwent Radical Prostatectomy, comparing those characterized by a relapse to those who are not characterized by a relapse. The first step has been the identification of subjects with a diagnosis of PC in Friuli Venezia Giulia (15079 cases) from Tumor’s register (data available from 1995 to 2009). In a second phase, subjects with only one tumor (PC) were selected (11521 people). Later, data on subjects, were crossed with data about medications (especially those related to prostatic problems) which were taken by these 2915 subjects. From data obtained, were selected those subjects underwent to Radical Prostatectomy (RP) (530 people) to whom was possible extract clinical information more detailed (TNM, Gleason score, PSA etc., obtaining 149 people). Finally, the last selection was based to the availability of biological samples (paraffin-embedded prostates specimens) on pathological anatomy, which were available for 122 patients. People selected were divided into people characterized by a disease relapse (PC) and subjects without a relapse (for whom no relapse was documented). The purpose of the two groups identified above was to understand if there were some differences in terms of methylation (related to the promoter of GSTP1), hence to determine whether this elements can influence the risk of relapse. During the studied period (from 1998 to 2014) in Friuli Venezia Giulia, the class of medications most used from patients with PC is that including Hormonal Preparations (HP), which shows a continuous increase, whereas the use of antiandrogens medications (AA) shows a decrease over time with the exception of new antiandrogens medications (belonging to the AAO class). The results show that people with higher levels of methylation have a higher risk of relapse, compared to those subjects with lower levels of methylation. Additionally, a higher Gleason score increases the risk of relapse, as shown in many papers in literature. The results obtained from Cox models shows that bivariate models (adjusted by age) are characterized by a trend of relapse’s risk, which increases with levels of methylation. This trend is not maintained in multiple models. In conclusion, the methylation of GSTP1 promoter might be useful to identify patients with higher risk of biochemical recurrence, however further studies based on an epidemiologic epigenetic approach are neededopenDottorato di ricerca in Scienze biomediche e biotecnologicheembargoed_20180930Cosano, Giorgi

    Polypharmacy and the use of medications in inpatients with acquired brain injury during post-acute rehabilitation: A cross-sectional study

    No full text
    Background: This study assessed the use of medications during inpatient post-acute rehabilitation for acquired brain injury (ABI).Materials and methods: All inpatients with ABI undergoing post-acute rehabilitation in centres identified through the roster of the Italian Society for Rehabilitation Medicine were included. A designated physician in each centre collected information through a structured questionnaire. This study calculated (a) prevalence of medication use, (b) logistic regression Odds Ratio (OR), with 95% confidence interval (95% CI), of polypharmacy ( 65 6 medications).Results: A total of 484 patients (median age = 52 years, 63.4% men, median time from acute event = 18.5 weeks) were included; 33.8% had Rancho Los Amigos Levels of Cognitive Functioning Scale (RLAS) score 1-2, 8.1% had a score of 7-8, of whom 92.0% received medications, 51.8% had a score of 6-10, of whom 83.9% had at least one psychotropic medication and 66.9% had two or more; 51.8% received anti-epileptics, 32.1% anti-depressants, 14.5% anti-psychotics, peaking in RLAS 4 (37.3%) and decreasing in RLAS 7-8. Polypharmacy was directly associated with age (55-64 years, OR = 2.1; 95% CI = 1.1-4.1; 65 65 years, OR = 1.7; 95% CI = 0.9-3.3), inversely with RLAS score (1-2 vs 7-8, OR = 4.3; 95% CI = 1.9-9.8).Conclusion: Polypharmacy and concurrent use of psychotropic medications was common, raising concern about drug-drug interactions. Safety and effectiveness of medications should be monitored, particularly when used concurrently

    Polypharmacy and the use of medications in inpatients with acquired brain injury during post-acute rehabilitation: A cross-sectional study

    No full text
    <p><i>Background</i>: This study assessed the use of medications during inpatient post-acute rehabilitation for acquired brain injury (ABI).</p> <p><i>Materials and methods</i>: All inpatients with ABI undergoing post-acute rehabilitation in centres identified through the roster of the Italian Society for Rehabilitation Medicine were included. A designated physician in each centre collected information through a structured questionnaire. This study calculated (a) prevalence of medication use, (b) logistic regression Odds Ratio (OR), with 95% confidence interval (95% CI), of polypharmacy (≥ 6 medications).</p> <p><i>Results</i>: A total of 484 patients (median age = 52 years, 63.4% men, median time from acute event = 18.5 weeks) were included; 33.8% had Rancho Los Amigos Levels of Cognitive Functioning Scale (RLAS) score 1–2, 8.1% had a score of 7–8, of whom 92.0% received medications, 51.8% had a score of 6–10, of whom 83.9% had at least one psychotropic medication and 66.9% had two or more; 51.8% received anti-epileptics, 32.1% anti-depressants, 14.5% anti-psychotics, peaking in RLAS 4 (37.3%) and decreasing in RLAS 7–8. Polypharmacy was directly associated with age (55–64 years, OR = 2.1; 95% CI = 1.1–4.1; ≥ 65 years, OR = 1.7; 95% CI = 0.9–3.3), inversely with RLAS score (1-2 vs 7–8, OR = 4.3; 95% CI = 1.9–9.8).</p> <p><i>Conclusion</i>: Polypharmacy and concurrent use of psychotropic medications was common, raising concern about drug–drug interactions. Safety and effectiveness of medications should be monitored, particularly when used concurrently.</p

    Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey

    No full text
    Objective: Guidance on pharmacotherapy of neurobehavioural sequelae post-acquired brain injury (ABI) is limited. Clinicians face the choice of prescribing off-label. This survey assesses prescribing practice and off-label use of psychotropic medications in Italian brain injury rehabilitation centres and factors associated with atypical antipsychotics use. Materials and methods: Centres were identified through the roster of the Italian Society for Rehabilitation Medicine. Information was collected through a structured questionnaire. This study calculated the prevalence of centres reporting to use off-label individual medications and unconditional logistic regression Odds Ratio (OR), with 95% confidence interval (95% CI) of atypical antipsychotics use. Results: Psychotropic medications were commonly used. More than 50% of the 35 centres (participation ratio 87.5%) reported to use off-label selected antipsychotics, mostly for agitation (90.5%) and behavioural disturbances (19.0%), and antidepressants, mostly for insomnia (37.5%) and pain (25.0%). Atypical antipsychotic use was directly associated with age <40 years (OR=2.68; 95% CI=1.25-5.76), recent ABI (1.74; 0.74-4.09), not with reported off-label use (0.98; 0.44-2.18). Conclusion: In clinical practice, the effectiveness and safety of medications, in particular off-label, should be systematically monitored. Studies are needed to improve the quality of evidence guiding pharmacotherapy and to evaluate effectiveness and safety of off-label prescribin
    corecore